PORTFOLIO NEWS Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis May 18, 2022 Read More » Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas May 17, 2022 Read More » Kallyope and Sosei Heptares Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR Targets for Drug Discovery May 17th, 2022 Read More » Remix Therapeutics Closes $70 Million Series B Financing May 17, 2022 Read More » Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Disease May 16, 2022 Read More » NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors May 12, 2022 Read More » Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update May 11, 2022 Read More » RAPT Therapeutics Reports First Quarter 2022 Financial Results May 11, 2022 Read More » Surrozen Reports First Quarter 2022 Financial Results May 11, 2022 Read More » eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update May 10, 2022 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis May 18, 2022 Read More »
Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas May 17, 2022 Read More »
Kallyope and Sosei Heptares Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR Targets for Drug Discovery May 17th, 2022 Read More »
Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Disease May 16, 2022 Read More »
NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors May 12, 2022 Read More »
Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update May 11, 2022 Read More »
eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update May 10, 2022 Read More »
